

## **ANNIKA MUSKANTOR IS APPOINTED NEW CEO OF BLUEFISH PHARMACEUTICALS**

Bluefish Pharmaceuticals has appointed Annika Muskantor as its new CEO, effective April 1<sup>st</sup>, 2025. With a strong background in the pharmaceutical, medtech and healthtech sectors, Annika brings extensive experience from different leading positions at e.g. Sobi, Oncopeptides, FRISQ, IRRAS and Scienta Omicron. As an experienced leader, Annika has successfully collaborated with dedicated teams to navigate complex challenges and drive operational improvements in both publicly listed and privately held companies.

Annika holds a double Bachelor's degree in Economics and German from Northwestern University and an MBA from the Kellogg School of Management.

"With Annika Muskantor, we gain a business leader with a broad and solid competence, capable of continuing the development of Bluefish Pharmaceuticals and leading the company through its next phase of growth.", says Gunilla Spongh, Chairman of the Board of Bluefish Pharmaceuticals.

"I am honored to join Bluefish Pharmaceuticals at this pivotal time. I look forward to working with our dedicated team to build a leading provider that delivers strong financial performance and strategic insight for our stakeholders, while remaining focused on the patients who rely on us for safe, effective and affordable medicines. We are committed to staying in the forefront of the generic drug market, continuously seizing new opportunities to enhance care and improve lives," says, Annika Muskantor.

"I would also like to take this opportunity to thank Erik Ekman for his hard work and valuable achievements during his years at Bluefish Pharmaceuticals," says Gunilla Spongh.

For more information contact:

Gunilla Spongh, Chairman of the Board, tel.+46 70 935 25 33

Gerald Engström, CEO of Färna Invest, tel. +46 70 519 00 01

### ***Bluefish Pharmaceuticals in brief:***

*Founded in Sweden in 2005, with its long tradition of industrial entrepreneurship, Bluefish Pharmaceuticals has become one of the most progressive Swedish pharmaceutical companies for generic products. The company focuses exclusively on development and sale of generic drugs. At Bluefish, we strive to make quality medicines accessible to more people. We create value in the full pharmaceutical value chain from developing to successfully marketing generic pharmaceuticals and we take pride in doing this in an innovative, responsible and cost-efficient way. The product portfolio consists of about 80 products and is growing. Bluefish currently conducts operations in 13 countries in Europe. The company has its own development laboratory in Bangalore where we develop our own generic products.*

[www.bluefishpharma.com](http://www.bluefishpharma.com)

BLUEFISH PHARMACEUTICALS AB  
Gävlegatan 22  
SE-113 30 Stockholm  
Sweden

Tel: +46 8 519 116 00  
Fax: +46 8 519 116 90  
[info@bluefishpharma.com](mailto:info@bluefishpharma.com)  
[www.bluefishpharma.com](http://www.bluefishpharma.com)